Shunji Takahashi

Summary

Affiliation: Cancer Institute Hospital
Country: Japan

Publications

  1. ncbi Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital
    Shunji Takahashi
    Department of Medical Oncology, Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, 135 8500, Japan
    Breast Cancer 13:8-15. 2006
  2. ncbi [Gene therapy for relapsed breast cancer]
    Shunji Takahashi
    Department of Clinical Chemotherapy and Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Nihon Rinsho 64:563-9. 2006
  3. ncbi [Evaluation of cancer-induced bone diseases by bone metabolic marker]
    Shunji Takahashi
    Japanese Foundation for Cancer Research, Cancer Institute Hospital, Department of Medical Oncology
    Clin Calcium 16:581- 90. 2006
  4. doi In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate
    Junko Mitsuhashi
    Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan
    J Gene Med 12:596-603. 2010
  5. doi Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
    Shunji Takahashi
    Department of Medical Oncology and Hematology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto ku, Tokyo, Japan
    Breast Cancer Res Treat 133:685-93. 2012
  6. doi Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors
    Shunji Takahashi
    The Cancer Institute Hospital of JFCR, Medical Oncology, Tokyo, Japan
    Cancer Sci 102:2058-64. 2011
  7. ncbi Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels
    S Takahashi
    Department of Medical Oncology, Cancer Institute Hospital, 1 37 1 Kami Ikebukuro, Toshima ku, Tokyo 170 8455, Japan
    Endocr Relat Cancer 10:403-7. 2003
  8. ncbi Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
  9. doi Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
  10. doi Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine
    Yoshinori Ito
    Department of Medical Oncology, The Cancer Institute of Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 16:126-31. 2009

Detail Information

Publications65

  1. ncbi Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital
    Shunji Takahashi
    Department of Medical Oncology, Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, 135 8500, Japan
    Breast Cancer 13:8-15. 2006
    ..Two patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. Both patients are in complete remission and had no apparent adverse effects from the MDR1 gene transfer...
  2. ncbi [Gene therapy for relapsed breast cancer]
    Shunji Takahashi
    Department of Clinical Chemotherapy and Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Nihon Rinsho 64:563-9. 2006
    ..Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer...
  3. ncbi [Evaluation of cancer-induced bone diseases by bone metabolic marker]
    Shunji Takahashi
    Japanese Foundation for Cancer Research, Cancer Institute Hospital, Department of Medical Oncology
    Clin Calcium 16:581- 90. 2006
    ..These findings suggest that bone metabolic markers would be useful to detect, to monitor, and to predict prognosis of bone metastases...
  4. doi In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate
    Junko Mitsuhashi
    Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan
    J Gene Med 12:596-603. 2010
    ..We report the analysis of MDR1-transduced cells in this patient...
  5. doi Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
    Shunji Takahashi
    Department of Medical Oncology and Hematology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto ku, Tokyo, Japan
    Breast Cancer Res Treat 133:685-93. 2012
    ..3-5.4%; p < 0.001). At 12 months, upfront zoledronic acid therapy prevented bone loss in postmenopausal Japanese women who were receiving adjuvant letrozole, confirming the Z-/ZO-FAST study results in western populations...
  6. doi Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors
    Shunji Takahashi
    The Cancer Institute Hospital of JFCR, Medical Oncology, Tokyo, Japan
    Cancer Sci 102:2058-64. 2011
    ..In this study population, the safety profile of dasatinib was generally acceptable and 150 mg of dasatinib administered once daily was determined to be the MTD...
  7. ncbi Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels
    S Takahashi
    Department of Medical Oncology, Cancer Institute Hospital, 1 37 1 Kami Ikebukuro, Toshima ku, Tokyo 170 8455, Japan
    Endocr Relat Cancer 10:403-7. 2003
    ..Our observations indicate that high plasma levels of PTHrP in cancer-bearing patients contribute not only to the development of hypercalcemia, but also to the development of the syndrome caused by an excess of pro-inflammatory cytokines...
  8. ncbi Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Cancer Chemother Pharmacol 63:865-71. 2009
    ....
  9. doi Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy
    Tomo Osako
    Division of Pathology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:233-41. 2010
    ....
  10. doi Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine
    Yoshinori Ito
    Department of Medical Oncology, The Cancer Institute of Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 16:126-31. 2009
    ..We have retrospectively examined the efficacy and safety of S-1 in patients with MBC who had been previously treated with anthracycline, taxane, and capecitabine...
  11. doi Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma
    Kazuhito Suzuki
    Department of Medical Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31 Ariake, Koto ku, Tokyo 1358550, Japan
    Jpn J Clin Oncol 43:37-44. 2013
    ..Prognostic predictors for newly diagnosed malignant lymphoma are well known. However, they have not been compared for patients with recurrent or refractory malignant lymphoma...
  12. doi Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib
    Takeshi Yuasa
    Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    BJU Int 109:1349-54. 2012
    ..The application of the MSKCC model distinctly separated OS curves (P<0.001), suggesting that MSKCC prognostic factors might be still valid to predict survival in metastatic RCC in the era of molecular targeted therapy...
  13. ncbi Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Cancer Chemother Pharmacol 62:159-64. 2008
    ..We retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer (MBC)...
  14. ncbi High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy
    Tomo Osako
    Divisions of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    J Cancer Res Clin Oncol 136:1431-8. 2010
    ..To determine the highly sensitive and highly resistant subsets to cytotoxic chemotherapy, we evaluated predictive factors for pCR and PD to NAC, and assessed the similarities in these factors...
  15. ncbi Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience
    Keiko Furukawa
    Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan
    Breast Cancer 13:329-33. 2006
    ..Trastuzumab is a humanized monoclonal antibody with specificity to the HER-2 protein. We evaluated the safety and efficacy of combined trastuzumab and paclitaxel therapy in women with metastatic breast cancer...
  16. doi Increased incidence of interstitial pneumonia by CHOP combined with rituximab
    Daisuke Ennishi
    Department of Oncology and Hematology, Cancer Institute Hospital, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Int J Hematol 87:393-7. 2008
    ..jirovecii and fungal infection. The need for prophylactic antifungals and ST during R-CHOP should be evaluated by randomized controlled trials...
  17. ncbi Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer
    Yoshimi Ide
    Department of Breast Surgery, Japanese Foundation for Cancer Research, 3 10 6 Ariake, Koto ku, Tokyo, Japan
    Breast Cancer 20:367-70. 2013
    ..Moreover, with positive HBsAb or/and HBcAb patients, HBV-DNA should be checked before starting chemotherapy and monitored during chemotherapy by a sensitive PCR method. ..
  18. ncbi Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer
    Junko Mitsuhashi
    Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Hum Gene Ther 18:895-906. 2007
    ..Our results thus show that docetaxel may have been effective in promoting the expansion of several MDR1-transduced clones in patient 1, but that they persist in the peripheral blood for only a few years...
  19. ncbi Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
    Yosuke Yasuda
    Department of Urology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, 3 8 31 Ariake, Koto ku, Tokyo, 135 8550, Japan
    Int J Clin Oncol 18:884-9. 2013
    ..Therefore, we further evaluated the prognostic impact of CRP for patients with metastatic renal cell carcinoma treated with molecular-targeted agents of tyrosine kinase inhibitors...
  20. doi Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas
    Kenji Nakano
    Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    Jpn J Clin Oncol 42:697-703. 2012
    ..The aim of this study was to evaluate the response of poorly differentiated neuroendocrine carcinoma to the combination of irinotecan and cisplatin in one institution...
  21. doi Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma
    Yasuhito Terui
    Departments of Medical Oncology and Hematology, Division of Clinical Chemotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan
    Clin Cancer Res 15:2523-30. 2009
    ..With increasing use, resistance to rituximab is a continuing concern, but CD20 mutation as a cause of resistance has not previously been reported...
  22. ncbi High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Breast Cancer 13:172-8. 2006
    ..We have summarized a single-center experience involving IBC patients. Our objectives are to clarify molecular alterations of HER-2/neu and p53 in IBC and to investigate the prognostic factors...
  23. ncbi Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients
    Shunji Takahashi
    Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135 8500, Japan
    Cancer Sci 98:1609-16. 2007
    ..A third patient received transplantation of the MDR1-transduced cells in 2004. These results suggest the feasibility of our MDR1 gene therapy against metastatic breast cancer, and follow-up is ongoing...
  24. doi Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes
    Masahiko Tanabe
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Breast Cancer 16:301-6. 2009
    ..However, no standard chemotherapy has been fully established for MBC patients pretreated with anthracycline and taxanes...
  25. ncbi Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma
    Yosuke Yasuda
    Department of Urology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, 3 8 31, Ariake, Koto ku, Tokyo, 135 8550, Japan
    Int J Clin Oncol 18:877-83. 2013
    ..However, it remains unclear whether bisphosphonates improve overall survival (OS) for renal cell carcinoma (RCC) patients with bone metastases...
  26. doi Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas
    Noriko Nishimura
    Division of Medical Oncology Hematology, Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo, Japan
    Support Care Cancer 20:2053-9. 2012
    ..The purpose was to determine the incidence and severity of OM and its sequelae in patients receiving conventional chemotherapy for various malignancies...
  27. doi High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone
    Kazuhito Suzuki
    Department of Medical Hematology Oncology, Cancer Institute Hospital, Tokyo, Japan
    Leuk Lymphoma 53:849-54. 2012
    ..001). High TK activity predicts poor overall survival among patients with newly diagnosed PTCL treated with CHOP. Response to CHOP treatment is significantly decreased in patients with PTCL with high TK activity...
  28. doi Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
    Takeshi Yuasa
    Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    Cancer Sci 102:1949-57. 2011
    ..Although further validation and implementation is necessary, if validated, biomarkers will help measure the therapeutic response in individual patients and establish treatment strategies for metastatic RCC...
  29. ncbi Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Tumori 90:40-3. 2004
    ..It became available in Japan in June 2001. This study focuses on the efficacy and safety of trastuzumab as a single agent in second-third line treatment of HER2/neu-overexpressing metastatic breast cancer...
  30. doi Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane
    Yuko Okanami
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3 10 6 Ariake, Koto ku, Tokyo, Japan
    Breast Cancer 18:182-8. 2011
    ..The purpose of this study was to determine the incidence of amenorrhea among breast cancer patients aged 40 years and younger following adjuvant chemotherapy...
  31. doi Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis
    Takeshi Yuasa
    Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Koto ku, Tokyo, Japan
    Clin Exp Metastasis 28:405-11. 2011
    ..In this population, MSKCC scores were valid predictors of survival. With increased treatment options, RCC patients with bone metastasis may benefit further from subsequent modalities and/or agents...
  32. ncbi Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan
    Hisakazu Nishimori
    Division of Medical Oncology and Hematology, Cancer Institute Hospital, Koto ku, Tokyo 135 8550, Japan
    Acta Med Okayama 64:285-91. 2010
    ..In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer...
  33. ncbi Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
    Tumori 93:129-32. 2007
    ..The purpose of the present retrospective study was to evaluate efficacy and safety of a lower dose-intensity capecitabine monotherapy regimen in heavily pretreated patients with metastatic breast cancer...
  34. doi Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer
    Yoshinori Ito
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Breast Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan
    Cancer Sci 102:130-6. 2011
    ..However, this study suggests that a randomized phase II study is a robust tool for obtaining a rapid conclusion on the usefulness of biomarkers and could be the foundation for further large clinical trials...
  35. ncbi Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis
    Mitsuru Koizumi
    Department of Nuclear Medicine, Cancer Institute Hospital, 1 37 1 Kami Ikebukuro, Toshima ku, Tokyo 170 8455, Japan
    Anticancer Res 23:4095-9. 2003
    ..The serum level of 3 different bone resorption markers in cancer patients with or without skeletal metastasis was compared to see whether the markers exhibit clinically significant differences useful for metastatic screening...
  36. doi A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer
    Mari Hosonaga
    Department of Medical Oncology, Cancer Institute Hospital, 3 8 31 Ariake, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 19:329-34. 2012
    ..In patients with MBC, the treatment objective is durable response with minimum toxicity. In Japan, the approved dose of docetaxel is 60-70 mg/m(2) every 3 weeks, whereas 75-100 mg/m(2) docetaxel is common in the West...
  37. ncbi Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer
    Keiichiro Tada
    Department of Breast Oncology, Cancer Institute Hospital, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Breast Cancer 13:279-83. 2006
    ..Few reports have addressed the feasibility and safety of classic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) therapy in Japanese female breast cancer patients...
  38. ncbi Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study
    Masataka Sawaki
    Department of Medical Oncology, Cancer Institute Hospital and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan
    Tumori 90:36-9. 2004
    ..We evaluated retrospectively the efficacy and toxicity of paclitaxel in patients with docetaxel-resistant metastatic breast cancer...
  39. doi Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study
    Yoshinori Ito
    Breast Cancer Division, Department of Medical Oncology, The Cancer Institute of the Japanese Foundation for Cancer Research, 3 8 31 Ariake Koto ku, Tokyo 135 8550, Japan
    Jpn J Clin Oncol 42:278-86. 2012
    ..This Phase 1 dose-escalation study assessed the safety, tolerability, maximum-tolerated dose, antitumor activity and pharmacokinetics of neratinib in Japanese patients with advanced solid tumors...
  40. doi Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer
    Takeshi Yuasa
    Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan
    Urology 77:831-5. 2011
    ..To select the patients who can benefit the most from treatment with targeted agents, it will be necessary to find a tumor characteristic that predicts their effectiveness...
  41. ncbi Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
    Yoshinori Ito
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
    Breast Cancer 14:156-62. 2007
    ..If these approaches overcome the limitations of trastuzumab, lapatinib will become an effective treatment option for breast cancer in the near future...
  42. ncbi Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab
    Yasuhito Terui
    Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135 8550, Japan
    Cancer Sci 97:72-9. 2006
    ..This observation gives us a novel strategy to suppress bulky disease-related resistance to monoclonal antibody treatment...
  43. ncbi Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer
    Mitsuru Koizumi
    Department of Nuclear Medicine, Internal Medicine, Cancer Institute Hospital, Japan
    Breast Cancer 10:21-7. 2003
    ..Even though bone resorption markers are a good tool to monitor response to bisphosphonate therapy, there remains the question of which class of bone resorption markers is best suited to the task...
  44. doi Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients
    Nahomi Tokudome
    Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3 8 31 Ariake, Koto ku, Tokyo, 135 8550, Japan
    Breast Cancer 18:195-202. 2011
    ..We conducted this study to determine the presence of CTCs with the CellSearch System™ and the clinical significance in treatment of metastatic breast cancer (MBC)...
  45. ncbi Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy
    Daisuke Ennishi
    Department of Medical Oncology and Hematology, Cancer Institute Hospital, Tokyo, Japan
    Am J Hematol 83:59-62. 2008
    ..Further studies will be necessary to investigate more fully the relationship between changes in HCV viral load and liver function during chemotherapy for HCV-infected patients...
  46. ncbi Flare-up of dermatomyositis along with recurrence of breast cancer
    Tomo Osako
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Breast J 13:200-2. 2007
    ....
  47. doi [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL]
    Shunji Takahashi
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Fonundation for Cancer Research
    Clin Calcium 21:447-53. 2011
    ..Oral or intravenous bisphosphonates are effective for prevention of CTIBL, and RANKL antibody (denosumab) is also effective. During treatment, physicians should follow bone mineral density and avoid QOL impairment due to osoteoporosis...
  48. ncbi Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma
    Yuko Mishima
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Toshima ku, Tokyo
    Cancer 101:1437-44. 2004
    ..In the current study, the authors investigated the effect and tolerability of the combination of chemotherapy, radiotherapy, and peripheral blood stem cell transplantation (PBSCT)...
  49. ncbi [Gene therapy for breast cancer]
    Shunji Takahashi
    Department of Medical Oncology, Cancer Institute Hospital
    Nihon Rinsho 63:476-82. 2005
    ..2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Both patients are in complete remission and have no apparent adverse effect from mdr1 gene transduction...
  50. ncbi [Bone metabolic markers for evaluation of bone metastases]
    Shunji Takahashi
    Department of Medical Oncology, Japanese Foundation for Cancer Research, Japan
    Clin Calcium 23:391-400. 2013
    ..Those bone metabolic markers are useful for : (1) diagnosis of bone metastases, (2) follow-up during treatment of bone metastases, and (3)predicting prognosis of bone metastases...
  51. doi Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients
    Takeshi Yuasa
    Department of Medical Oncology and Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Urology 75:1131-7. 2010
    ..However, our previous cross-sectional study revealed that short-term ADT (average, 23.5 months) does not significantly increase the prevalence of osteoporosis in Japanese patients...
  52. doi Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case
    Takashi Akiyoshi
    Department of Gastroenterological Surgery, Cancer Institute Hospital, 3 10 6 Ariake, Koto ku, Tokyo, 135 8550, Japan
    Surg Today 40:272-6. 2010
    ..We report this case to show that there is the possibility of curative salvage surgery after long-term imatinib treatment in some patients with peritoneal metastases of a GIST...
  53. doi [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)]
    Shunji Takahashi
    Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
    Clin Calcium 21:1239-47. 2011
    ..During cancer treatment with gonadal dysfunction, bone mineral density should be carefully followed to avoid QOL impairment due to osoteoporosis...
  54. pmc Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
    Yoshie Nakayama
    Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
    Case Rep Oncol 6:50-4. 2013
    ..The aim of this report is to underline possible risks associated with the new combination chemotherapy...
  55. ncbi [Molecular-target therapy for advanced malignant melanoma]
    Shunji Takahashi
    Dept of Medical Oncology, Japanese Foundation for Cancer Research, Japan
    Gan To Kagaku Ryoho 40:19-25. 2013
    ..These two types of targeting therapy are expected to be standard therapies for melanoma...
  56. ncbi Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience
    Katsuki Sugiyama
    Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
    Cancer 94:594-600. 2002
    ..In the current study, the authors investigated the efficacy and adverse effects of irinotecan in the treatment of recurrent and refractory non-Hodgkin lymphoma, for which current therapies appear to be unsatisfactory...
  57. ncbi [Gene therapy for breast cancer]
    Shunji Takahashi
    Department of Clinical Chemotherapy and Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Nihon Rinsho 65:135-41. 2007
  58. ncbi [Pancreatic islet cell carcinoma with multiple hepatic metastases successfully treated with a streptozocin/5-FU regimen--a case report]
    Yasuhiro Arakawa
    Dept of Medical Oncology, Cancer Institute Hospital
    Gan To Kagaku Ryoho 29:2561-4. 2002
    ..Only grade 1 nausea and alopecia were observed during the treatment. No hematological toxicity was observed, nor, with sufficient diuresis, was nephrotoxicity, demonstrating that this regimen can be administered safely...
  59. ncbi [Gene therapy for breast cancer]
    Shunji Takahashi
    Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
    Gan To Kagaku Ryoho 30:468-77. 2003
    ..Both patients are in complete remission and have no apparent adverse effect from MDR1 gene transduction...
  60. ncbi [Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report]
    Eijiro Nagasaki
    Dept of Medical Oncology, Cancer Institute Hospital
    Gan To Kagaku Ryoho 30:1523-7. 2003
    ..Cytomorphologically, the pleural fluid specimen showed both atypical lymphoid cells and adenocarcinoma cells simultaneously. Existence of double cancer in the pleural effusion has not been reported, suggesting that this case is rare...
  61. ncbi Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma
    Daisuke Ennishi
    Leuk Lymphoma 48:2241-3. 2007
  62. ncbi [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]
    Hisakazu Nishimori
    Dept of Medical Oncology, Cancer Institute Hospital
    Gan To Kagaku Ryoho 32:671-3. 2005
    ..Poorly-differentiated neuroendocrine carcinomas like this case are highly sensitive to chemotherapy, and a careful pathological diagnosis may clarify its sensitivity to chemotherapy and the prognosis...
  63. ncbi Leupeptin-sensitive proteases involved in cell survival after X-ray irradiation in human RSa cells
    Hong chang Zhang
    Department of Environmental Biochemistry, Graduate School of Medicine, Chiba University, Chuoku, Japan
    Cell Biol Int 29:662-8. 2005
    ..These results suggest that leupeptin-sensitive proteases are involved in the resistance of human RSa cells to X-ray cell-killing...
  64. ncbi Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines
    Hisayo Kubota
    Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Inohana, Japan
    Int J Radiat Biol 81:701-9. 2005
    ..Glucose regulated protein 94 (GRP94) is a molecular chaperone, which increases in amount after X-ray irradiation. This study examined the involvement of GRP94 in radio-resistance in human cervical cancer cells...
  65. pmc Surrogate splicing for functional analysis of sesquiterpene synthase genes
    Shuiqin Wu
    Plant Physiology, Biochemistry and Molecular Biology Program, Department of Plant and Soil Sciences, University of Kentucky, Lexington, Kentucky 40546 0312
    Plant Physiol 138:1322-33. 2005
    ....